Orchid Chemicals & Pharmaceuticals Ltd today said it has received approval from the USFDA for its ANDA (Abbreviated New Drug Application) of Cephalexin oral suspension.
Orchid Chemicals & Pharmaceuticals Ltd today said it has received approval from the USFDA for its ANDA (Abbreviated New Drug Application) of Cephalexin oral suspension.
Cephalexin, an off-patent molecule, forms part of Orchid Chemicals' distribution alliance with US generic pharma major Par Pharmaceuticals Inc, it informed the Bombay Stock Exchange.Orchid added that its Cephalexin capsules are already marketed in the US through partnership with Par Pharmaceuticals and following this approval, the number of dosage forms, oral solids and injections distributed by it in the US now stands at 12.
The company's shares were trading at Rs 185.30, up 1.12 per cent at the BSE.
Source:PTI News
